Tweet
Antimicrob Agents Chemother. Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections
[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]
------
Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections
Natalie K. Boyd<SUP>a</SUP>, Cindy L. Zoellner<SUP>a</SUP>,<SUP>b</SUP>, Mark A. Swancutt<SUP>a</SUP>,<SUP>b</SUP> and Kavita P. Bhavan<SUP>a</SUP>,<SUP>b</SUP>
<SUP></SUP>
Author Affiliations: <SUP>a</SUP>Parkland Health and Hospital System <SUP>b</SUP>University of Texas Southwestern Medical Center, Dallas, Texas, USA
ABSTRACT
Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole ?boosting? effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.
FOOTNOTES
Received 4 April 2012. Returned for modification 18 June 2012. Accepted 7 August 2012.
Address correspondence to Natalie Boyd, natalie.boyd@phhs.org.
Published ahead of print 13 August 2012
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
-<SUP></SUP>
Author Affiliations: <SUP>a</SUP>Parkland Health and Hospital System <SUP>b</SUP>University of Texas Southwestern Medical Center, Dallas, Texas, USA
ABSTRACT
Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole ?boosting? effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.
FOOTNOTES
Received 4 April 2012. Returned for modification 18 June 2012. Accepted 7 August 2012.
Address correspondence to Natalie Boyd, natalie.boyd@phhs.org.
Published ahead of print 13 August 2012
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
------